Shares of Biohaven Pharmaceutical Holding Co Ltd. (BHVN) tumbled 5.90% in after-hours trading on Wednesday, following an announcement that the U.S. Food and Drug Administration (FDA) has extended the review period for the company's New Drug Application (NDA) for troriluzole.
The FDA has pushed back the Prescription Drug User Fee Act (PDUFA) date for troriluzole, Biohaven's investigational treatment for spinocerebellar ataxia, a rare genetic disease. This extension shifts the expected decision timeline, with the FDA's ruling now anticipated in the fourth quarter of 2025, rather than the previously expected earlier date.
This delay in the regulatory process for troriluzole, a key drug in Biohaven's pipeline, has clearly rattled investors. The extended review period not only pushes back potential revenue from the drug but also introduces additional uncertainty into the approval process. For a pharmaceutical company, delays in drug approvals can significantly impact financial projections and market confidence, which is reflected in the sharp after-hours stock decline.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。